Final KEYNOTE-564 data show Keytruda after kidney cancer surgery lowered the risk of death by 30%. Dr. Toni Choueiri explains what it means for patients.
|Articles|March 15, 2021
Recent News and Updates in Kidney Cancer
Author(s)Ryan McDonald
In honor of Kidney Cancer Awareness Month, CURE® compiled some recent kidney cancer news and updates patients may have missed.
Advertisement
There have been multiple updates in the field of kidney cancer over the past several weeks. In honor of Kidney Cancer Awareness Month, CURE® looks back at some of the latest news and updates affecting patients with that cancer type.
- A higher starting dose of Lenvima (lenvatinib), compared with a lower starting dose, prolonged the time that patients with renal cell carcinoma experienced negative effects on factors including social and physical functioning, financial difficulties and cogitative functioning over time.
READ MORE .
- Recent study results, according to one expert, show that Cabometyx (cabozantinib) should be considered the new standard for systemic therapy in patients with metastatic papillary renal cell carcinoma.
READ MORE . - The Food and Drug Administration recently granted approval to Fotivda (tivozanib) in adults with relapsed or refractory advanced renal cell carcinoma who have received two or more prior systemic therapies.
READ MORE . - The combination of Cabometyx (cabozantinib) plus Opdivo (nivolumab) “is certainly going to become one of the new standards of care” for the treatment of advanced renal cell carcinoma now that the regimen is approved, according to an expert from the Dana-Farber Cancer Institute.
READ MORE . - Positive results from the phase 3 CLEAR clinical trial are just one more dataset that could offer “a sense of hope and promise” for patients with advanced renal cell carcinoma, says the study’s lead author, Dr. Robert J. Motzer.
WATCH HERE . - Patients with metastatic renal cell carcinoma older than 75 years experienced more toxicity with mTOR inhibitors, tyrosine kinase inhibitors and checkpoint immunotherapy compared with those younger than 75 years, but researchers found that age did not impact outcomes like progression-free survival and overall survival.
READ MORE .
For more news on cancer updates, research and education, don’t forget to
Advertisement
Related to this article
Ohio State hematologist Dr. Kerry Rogers says chemotherapy and newer targeted drugs both work well, and the right choice depends on the patient.
Given an 18-month prognosis for peritoneal mesothelioma in 2007, a mother shares the joy of tapping her son out at his Air Force basic training graduation.
A once-daily oral pill gives patients with symptomatic TGCT another option when surgery could cause more harm than good.
For World NET Cancer Day, CURE answers seven common questions about neuroendocrine tumors, from carcinoid syndrome and Ki-67 to dotatate PET scans and treatment options.
Up to 40% of patients with classic hairy cell leukemia relapse within 10 to 15 years. An NIH researcher explains how adding Rituxan up front may help.
Gita Kwatra, PharmD, MBA, co-founder and CEO of the Glioblastoma Foundation, explains what happens to tumor tissue after brain surgery and how patients can ask their care team for genomic testing.
Most people with pancreatic cancer lose weight they didn't mean to. Here is how weight loss from poor digestion differs from cachexia, and what enzymes, eating strategies and appetite medicines can do.
Advertisement
Advertisement
Trending on CURE
1
FDA Approves Pimicotinib for Tenosynovial Giant Cell Tumor
2
Neuroendocrine Tumors: 7 Questions Patients Ask, Answered
3
Why Rituxan Plus Cladribine May Delay Hairy Cell Leukemia Relapse
4
Datroway Slows Brain Metastases in Triple-Negative Breast Cancer
5